Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.

BACKGROUND Despite rapid expansion of antiretroviral therapy (ART) in sub-Saharan Africa there are few longitudinal data describing programme performance during rapid scale-up. METHODS We compared mortality, viral suppression and programme retention in 3 consecutive years of a public sector community-based ART clinic in a South African township. Data were collected prospectively from establishment of services in October 2002 to the censoring date in September 2005. Viral load and CD4 counts were monitored at 4-monthly intervals. Community-based counsellors provided adherence and programme support. RESULTS During the study period 1139 ART-naïve patients received ART (161, 280 and 698 in the 1st, 2nd and 3rd years respectively). The median CD4 cell counts were 84 cells/microl (interquartile range (IQR) 42-139), 89 cells/microl (IQR 490-149), and 110 cells/microl (IQR 55-172), and the proportions of patients with World Health Organization (WHO) clinical stages 3 and 4 were 90%, 79% and 76% in each sequential year respectively. The number of counsellors increased from 6 to 28 and the median number of clients allocated to each counsellor increased from 13 to 33. The overall loss to follow-up was .9%. At the date of censoring, the Kaplan-Meier estimates of the proportion of patients still on the programme were 82%, 86% and 91%, and the proportion who were virally suppressed (< 400 copies/ml) were 100%, 92% and 98% for the 2002, 2003 and 2004 cohorts respectively. CONCLUSIONS While further operational research is required into optimal models of care in different populations across sub-Saharan Africa, these results demonstrate that a single community-based public sector ART clinic can extend care to over 1000 patients in an urban setting without compromising programme performance.

[1]  E. Delaporte,et al.  Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Saba,et al.  Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire , 2003, AIDS.

[3]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[4]  L. Myer,et al.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.

[5]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[6]  A. Calmy,et al.  Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières , 2003, AIDS.

[7]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Harries,et al.  Preventing antiretroviral anarchy in sub-Saharan Africa , 2001, The Lancet.

[9]  T. Adam,et al.  Capacity constraints to the adoption of new interventions: consultation time and the Integrated Management of Childhood Illness in Brazil. , 2005, Health policy and planning.

[10]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[11]  C.G.A. Mcgregor Progress on Global Access to HIV Antiretroviral Therapy , 2006 .

[12]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[13]  R. Salamon,et al.  Medium-Term Survival, Morbidity and Immunovirological Evolution in HIV-Infected Adults Receiving Antiretroviral Therapy, Abidjan, Côte D'Ivoire , 2002, Antiviral therapy.

[14]  G. Schierhout,et al.  An assessment of care provided by a public sector STD clinic in Cape Town , 1998, International journal of STD & AIDS.

[15]  L. Bekker,et al.  Antiretroviral therapy in a community clinic--early lessons from a pilot project. , 2003, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[16]  C Sabine AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? , 2005, AIDS.

[17]  A. Harries,et al.  Tuberculosis and HIV interaction in sub‐Saharan Africa: impact on patients and programmes; implications for policies , 2005, Tropical medicine & international health : TM & IH.

[18]  C. Gilks,et al.  Scaling up treatment--why we can't wait. , 2005, The New England journal of medicine.